Global Preimplantation Genetic Testing Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The Preimplantation Genetic Testing Market size is expected to reach USD 2587.76 Million in 2034 from USD 1021.51 Million (2025) growing at a CAGR of 10.88% during 2026-2034.

The global preimplantation genetic testing market is growing rapidly as assisted reproductive technologies become more advanced and widely adopted. Preimplantation genetic testing (PGT) is used during in vitro fertilization (IVF) to screen embryos for genetic abnormalities before implantation. This process helps improve the chances of a successful pregnancy and reduces the risk of genetic disorders.

A major driver of the market is the increasing prevalence of genetic diseases and infertility issues among couples worldwide. As awareness of genetic screening increases, more patients are opting for advanced reproductive technologies. Additionally, improvements in genomic sequencing and genetic analysis technologies have made PGT more accurate and reliable.

Looking ahead, the preimplantation genetic testing market is expected to expand significantly as reproductive medicine continues to advance. The growing demand for personalized reproductive healthcare and improved IVF success rates will support market growth. Ongoing research in genetics and reproductive biology will likely create new opportunities for advanced embryo screening technologies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

Chromosomal Abnormalities
Aneuploidy
X-Linked Diseases
Single Gene Disorders
Hla Typing
Gender Selection
Others

By End User

Diagnostic Laboratories
Hospitals
Clinics
Others

COMPANIES PROFILED

Illumina Inc, Thermo Fisher Scientific Inc, Agilent Technologies Inc, PerkinElmer Inc, CooperSurgical Inc, Abbott Laboratories, Natera Inc, Takara Bio, Oxford Gene Technology, Yikon Genomics, Progenesis, Beijing Genomics Institute BGI, Invitae Corporation, Invicta Genetics, Genea Limited
We can customise the report as per your requirements.

Product Code: VMR11212794

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY TYPE 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Type
4.2. Chromosomal Abnormalities Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Aneuploidy Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. X-Linked Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Single Gene Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Hla Typing Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.7. Gender Selection Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY END USER 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast End User
5.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY REGION 2022-2034 (USD MN)

6.1. Regional Outlook
6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 6.2.1 By Type
- 6.2.2 By End User
- 6.2.3 United States
- 6.2.4 Canada
- 6.2.5 Mexico
6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 6.3.1 By Type
- 6.3.2 By End User
- 6.3.3 United Kingdom
- 6.3.4 France
- 6.3.5 Germany
- 6.3.6 Italy
- 6.3.7 Russia
- 6.3.8 Rest Of Europe
6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 6.4.1 By Type
- 6.4.2 By End User
- 6.4.3 India
- 6.4.4 Japan
- 6.4.5 South Korea
- 6.4.6 Australia
- 6.4.7 South East Asia
- 6.4.8 Rest Of Asia Pacific
6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 6.5.1 By Type
- 6.5.2 By End User
- 6.5.3 Brazil
- 6.5.4 Argentina
- 6.5.5 Peru
- 6.5.6 Chile
- 6.5.7 Rest of Latin America
6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 6.6.1 By Type
- 6.6.2 By End User
- 6.6.3 Saudi Arabia
- 6.6.4 UAE
- 6.6.5 Israel
- 6.6.6 South Africa
- 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

7.1. Recent Developments
7.2. Company Categorization
7.3. Supply Chain & Channel Partners (based on availability)
7.4. Market Share & Positioning Analysis (based on availability)
7.5. Vendor Landscape (based on availability)
7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PREIMPLANTATION GENETIC TESTING INDUSTRY

8.1. Top Companies Market Share Analysis
8.2. Company Profiles
- 8.2.1 Illumina Inc
- 8.2.2 Thermo Fisher Scientific Inc
- 8.2.3 Agilent Technologies Inc
- 8.2.4 PerkinElmer Inc
- 8.2.5 CooperSurgical Inc
- 8.2.6 Abbott Laboratories
- 8.2.7 Natera Inc
- 8.2.8 Takara Bio
- 8.2.9 Oxford Gene Technology
- 8.2.10 Yikon Genomics
- 8.2.11 Progenesis
- 8.2.12 Beijing Genomics Institute (BGI)
- 8.2.13 Invitae Corporation
- 8.2.14 Invicta Genetics
- 8.2.15 Genea Limited